Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A meta‐analysis

Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A... INTRODUCTIONNonischaemic dilated cardiomyopathy (DCM) is defined as left ventricular (LV) dilation and systolic dysfunction in the absence of coronary artery disease or abnormal loading conditions proportionate to the degree of LV impairment. As one of the leading causes of heart failure (HF), DCM (either ischaemic or nonischaemic) is the most frequent indication for ventricular assist device and/or cardiac transplantation. The major determinant of adverse outcomes in DCM is the extent of LV dilation and contractile impairment, while the key therapeutic goal was reversal of these abnormalities and LV reverse remodelling.Improving outcome of DCM remains a difficult goal to achieve. The treatment of HF due to DCM, other than standard pharmaceuticals and heart transplantation, is limited. To improve the prognosis and quality of life for HF patients, either due to ischaemic or nonischaemic causes, therapeutic strategies should alter the remodelling process, regenerate cardiomyocytes and repair myocardium. Heart has no intrinsic muscular regeneration capacity. To restore cardiac function and regenerate cardiomyocytes, regenerative medicine techniques are being increasingly investigated. As a potential therapeutic approach, cell‐based therapies have rapidly emerged. Different cell strains used include bone marrow mononuclear cells (BMMCs), G‐CSF‐stimulated autologous CD34+ peripheral blood stem cells (PBSC), embryonic stem cells (ESCs), skeletal http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Investigation Wiley

Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A meta‐analysis

Loading next page...
 
/lp/wiley/bone-marrow-derived-mononuclear-cell-therapy-for-nonischaemic-dilated-AUv0ODt3cA
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd
ISSN
0014-2972
eISSN
1365-2362
D.O.I.
10.1111/eci.12894
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONNonischaemic dilated cardiomyopathy (DCM) is defined as left ventricular (LV) dilation and systolic dysfunction in the absence of coronary artery disease or abnormal loading conditions proportionate to the degree of LV impairment. As one of the leading causes of heart failure (HF), DCM (either ischaemic or nonischaemic) is the most frequent indication for ventricular assist device and/or cardiac transplantation. The major determinant of adverse outcomes in DCM is the extent of LV dilation and contractile impairment, while the key therapeutic goal was reversal of these abnormalities and LV reverse remodelling.Improving outcome of DCM remains a difficult goal to achieve. The treatment of HF due to DCM, other than standard pharmaceuticals and heart transplantation, is limited. To improve the prognosis and quality of life for HF patients, either due to ischaemic or nonischaemic causes, therapeutic strategies should alter the remodelling process, regenerate cardiomyocytes and repair myocardium. Heart has no intrinsic muscular regeneration capacity. To restore cardiac function and regenerate cardiomyocytes, regenerative medicine techniques are being increasingly investigated. As a potential therapeutic approach, cell‐based therapies have rapidly emerged. Different cell strains used include bone marrow mononuclear cells (BMMCs), G‐CSF‐stimulated autologous CD34+ peripheral blood stem cells (PBSC), embryonic stem cells (ESCs), skeletal

Journal

European Journal of Clinical InvestigationWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial